- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04220827
Paclitaxel til behandling af gastrisk eller gastroøsofageal kræft
Et fase I-studie af intraperitoneal paclitaxel hos patienter med gastrisk adenocarcinom og karcinomatose eller positiv cytologi
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Studieoversigt
Status
Betingelser
- Peritoneal karcinomatose
- Klinisk fase IV gastrisk cancer AJCC v8
- Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Metastatisk gastrisk adenocarcinom
- Metastatisk Gastroøsofageal Junction Adenocarcinoma
- Postneoadjuverende terapi Stage IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stage IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stadium IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Klinisk fase IVA gastrisk cancer AJCC v8
- Klinisk fase IVB gastrisk kræft AJCC v8
- Patologisk fase IV mavekræft AJCC v8
- Klinisk fase IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stage IV gastrisk cancer AJCC v8
- Klinisk fase IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk Stage IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk stadium IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To assess the maximum tolerated dose (MTD) of paclitaxel via intraperitoneal route in subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis.
SECONDARY OBJECTIVES:
I. Safety and tolerability of escalating doses of intraperitoneal paclitaxel in subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis.
II. To make a preliminary assessment of the anti-tumor activity of paclitaxel in subjects with stage IV gastric or gastroesophageal cancer and positive cytology or carcinomatosis.
OUTLINE: This is a dose-escalation study.
Patients receive paclitaxel intraperitoneally (IP) over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- M D Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
-
Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction
-
Leukocytes >= 3,000/uL
-
Absolute neutrophil count >= 1,500/uL
-
Platelets >= 60,000/Ul
-
Serum creatinine =< 1.5 mg/dL
-
Distant metastatic disease of peritoneum:
- Positive peritoneal cytology
- Carcinomatosis on diagnostic laparoscopy or laparotomy
- Completion of preoperative systemic chemotherapy
Exclusion Criteria:
- Infections such as pneumonia or wound infections that would preclude protocol therapy
- Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who are not postmenopausal defined as no menses in greater than or equal to 12 months, have not had a hysterectomy or bilateral salpingo-ophorectomy, do not have ovarian failure, or have not had a surgical sterilization procedure) must agree to refrain from breast-feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence. Men with reproductive potential must agree to an appropriate method of birth control, including abstinence or double barrier method (diaphragm plus condom)
- Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure
- Subjects deemed unable to comply with study and/or follow-up procedures
- Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
- Previous surgery that would preclude safe diagnostic laparoscopy with port placement
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (paclitaxel)
Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity. |
Given IP
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events
Tidsramme: Up to after 30 days after treatment completion
|
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Safety data will be summarized using frequency tables by grade and attribution. |
Up to after 30 days after treatment completion
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Brian D Badgwell, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Peritoneale sygdomme
- Abdominale neoplasmer
- Peritoneale neoplasmer
- Organiske kemikalier
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Taxoider
- Cyclodecanes
- Diterpenes
- Sundhedsøkonomi og organisationer
- Økonomi
- Paclitaxel
- Skatter
Andre undersøgelses-id-numre
- 2019-0784
- 2019-0784 (Anden identifikator: M D Anderson Cancer Center)
- NCI-2019-08320 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .